The effect of sitagliptin on serum PAI-1 concentration in type 2 diabetic patient

The effect of sitagliptin on serum PAI-1 concentration in type 2 diabetic patient - Effect of sitagliptin on PAI-1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004657

Enrollment

Registered

2010-12-06

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

treatment with sitagliptin (50mg/day) Blood collection at 0, 2, or 4 months after administration of the agent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients treated without DPP-4 inhibitor

Exclusion criteria

Exclusion criteria: patients treated with insulin injection or GLP-1 receptor agonists

Design outcomes

Primary

Measure	Time frame
Serum PAI-1 concentration at 0, 2, or 4 months after administration of sitagliptin.	—

Secondary

Measure	Time frame
HbA1c, blood glucose level, BNP, or free fatty acids at 0, 2, or 4 months after administration of sitagliptin.	—

Countries

Japan

Contacts

Public ContactJun Shirakawa

Yokohama City University, Graduate School of Medicine Dept. of Endocrinology and Metabolism

045-787-2639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026